OncoMed Promotes

OncoMed Pharmaceuticals, a clinical-stage company developing therapeutics that target cancer stem cells, has promoted Jakob Dupont, formerly vice president, clinical research to senior vice president and chief medical officer. Privately-held, OncoMed’s investors include US Venture Partners, Latterell Venture Partners, The Vertical Group, Morgenthaler Ventures, Phase4 Ventures, Delphi Ventures, Adams Street Partners, De Novo Ventures, Bay […]

Transcend Medical Sews Up $51M Series B

Transcend Medical Inc., a Menlo Park, Calif.-based ophthalmic device company, has closed a second tranche of its Series B round, bringing the total to an eye-popping $51 million. Investors include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners. The company says it will use the funds to develop additional infrastructure and resources for a U.S. study of its micro-stent technology. The company is focused on minimally invasive glaucoma therapies.

Pulmonx Raises $32 Million

Pulmonx, an emerging leader in interventional pulmonology, announced today that it has concluded an agreement for a new round of equity financing from an investment syndicate led by two new investors. The company also announced that it plans to use this capital to support the international commercial launch of its Zephyr® Endobronchial Valve (EBV), and its recently approved Chartis® Pulmonary Assessment System. Both products are CE marked and cleared for sale in Europe and other major international markets. The company expects that this round of financing will fund the expansion of its commercial operations through to positive cash flow and profitability.

Pathway Medical Adds $1.5 To Series D

Pathway Medical Technologies, a developer of endovascular treatments for peripheral arterial disease received a $1.5 million investment from Washington Research Foundation, independent, nonprofit foundation, as part of the company’s Series D financing. The round totals $42.5 million with investments from Forbion Capital Partners, Giza Venture Capital, HLM Venture Partners, Latterell Venture Partners, and Oxford Bioscience […]

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget